Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Other Non-Current Assets (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Other Non-Current Assets for 9 consecutive years, with $13.0 million as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Assets rose 5.11% year-over-year to $13.0 million; the TTM value through Mar 2026 reached $13.0 million, up 5.11%, while the annual FY2025 figure was $12.8 million, 15.63% up from the prior year.
  • Other Non-Current Assets hit $13.0 million in Q1 2026 for Bicycle Therapeutics, up from $12.8 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $13.8 million in Q2 2025 and bottomed at $4.2 million in Q1 2022.
  • Average Other Non-Current Assets over 5 years is $9.3 million, with a median of $9.9 million recorded in 2024.
  • Year-over-year, Other Non-Current Assets surged 151.69% in 2023 and then tumbled 45.83% in 2024.
  • Bicycle Therapeutics' Other Non-Current Assets stood at $8.5 million in 2022, then plummeted by 31.52% to $5.8 million in 2023, then soared by 91.19% to $11.1 million in 2024, then grew by 15.63% to $12.8 million in 2025, then grew by 1.46% to $13.0 million in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $13.0 million, $12.8 million, and $13.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.